HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Chin, K. M. Articles by Rubin, L. J. PubMed Articles by Chin, K. M. Articles by Rubin, L. J.

STATE-OF-THE-ART PAPER

Pulmonary Arterial Hypertension

Kelly M. Chin, MD^_*,_* and Lewis J. Rubin, MD

^_* Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California.

Manuscript received November 29, 2007; revised manuscript received December 28, 2007, accepted January 6, 2008.

^_* Reprint requests and correspondence: Dr. Kelly M. Chin, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Mail Code 75390-8550, Dallas, Texas 75235. (Email: Kelly.Chin{at}utsouthwestern.edu).

Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes. Over this same period, the classification of pulmonary hypertension has been revised with changes including the substitution of the term idiopathic for primary PAH and an expanded list of conditions felt to be associated with the development of PAH. Long-term follow-up studies have provided better information on prognosis and expected outcomes with treatment, with particularly valuable data on reassessment of prognosis after treatment with epoprostenol. Combination therapy is more frequently being used, and limited data on novel therapies such as stem cell transplantation have been published. The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH.

Abbreviations and Acronyms   BMPR = bone morphogenetic protein receptor   CHF = congestive heart failure   HIV = human immunodeficiency virus   NO = nitric oxide   PAH = pulmonary arterial hypertension   RV = right ventricle/ventricular